Related Experiment Video
Updated: May 26, 2026
05:17
Percutaneous Endoscopic Unilateral-Approach Bilateral Decompression for Lumbar Spinal Stenosis
Published on: February 9, 2024
Senolytic Therapy as a Preventive Strategy for Spine Degeneration and Pain
Saber Ghazizadeh1,2,3, Hosni Cherif1,2, Matthew Mannarino1,2,3
1Department of Surgery, Orthopaedic Research Lab, McGill University, Montreal, Quebec, Canada.
Summary
Targeting cellular senescence with senolytic agents like o-vanillin and RG-7112 can prevent age-related spine degeneration and pain. Early intervention preserves spinal tissues and bone structure, offering a promising strategy for musculoskeletal health.
Area of Science:
- Biogerontology
- Musculoskeletal Health
- Pain Research
Background:
- Cellular senescence, a hallmark of aging, drives inflammation and tissue breakdown.
- Accumulated senescent cells are linked to spinal tissue degeneration and back pain.
Purpose of the Study:
- To investigate the efficacy of senolytic agents (o-vanillin and RG-7112) in preventing pain-related behaviors and spinal degeneration.
- To assess the impact of early senolytic intervention on senescence markers and pro-inflammatory factors in spinal tissues.
Main Methods:
- Administration of senolytic agents o-vanillin and RG-7112 to sparc-/- mice.
- Evaluation of pain-related behavior, senescence markers, and inflammatory factors in various spinal tissues.
- Assessment of intervertebral disc volume and vertebral bone microarchitecture.
Main Results:
- Senolytic treatment prevented pain-related behavior in mice.
- Reduced expression of senescence markers and pro-inflammatory factors in spinal tissues (intervertebral discs, vertebral endplates, bone, spinal cord).
- Preserved intervertebral disc volume and vertebral bone microarchitecture, indicating protection against structural degeneration.
Conclusions:
- Early senolytic intervention effectively mitigates degenerative changes and pain associated with aging.
- Senolytic therapy shows promise as a preventive strategy for age-related musculoskeletal decline and back pain.
